''
The Event in Detail: Strong 2025 Performance
GSK plc (NYSE: GSK) has demonstrated significant financial momentum throughout 2025, culminating in its stock price trading near a 52-week high of approximately $48.7 per share. The company's year-to-date gains are reported to be in the 30-40% range, substantially outperforming its pharmaceutical peer group. This performance is anchored by consecutive earnings beats in the second and third quarters.
In its Q3 2025 update, GSK reported an 8% increase in sales to £8.5 billion, driven by a 16% growth in its Specialty Medicines division. Following these results, the company upgraded its full-year 2025 guidance, projecting:
- Sales Growth: 6–7% (revised up from 3-5%)
- Core EPS Growth: 10–12% (revised up from 6-8%)
This robust performance has been underpinned by strong sales in HIV treatments, which rose 12%, and a 39% surge in oncology sales, driven by drugs like Jemperli and Ojjaara.
Market Implications: Blenrep's Revival and Strategic Deals
A pivotal event for GSK in 2025 was the revival of its multiple myeloma drug, Blenrep. After an FDA advisory committee voted against its approval in July, causing a more than 6% drop in the stock, the FDA granted a surprise approval on October 23, 2025. The drug, which demonstrated a 51% reduction in the risk of death in trials, is now positioned as a major growth driver. GSK maintains its forecast that Blenrep could exceed £3 billion in peak annual sales, turning a potential liability into a key component of its oncology strategy.
Further bolstering its pipeline, GSK announced a strategic collaboration with LTZ Therapeutics on November 19, 2025, to develop novel myeloid cell engagers in oncology. The deal includes a $50 million upfront payment to LTZ. However, the company also faces a legal challenge. On November 20, 2025, its subsidiary Tesaro filed a lawsuit against AnaptysBio, Inc., over the license agreement for the immunotherapy drug Jemperli, seeking a potential 50% reduction in payments. This introduces uncertainty but also potential financial upside if GSK prevails.
Expert Commentary: Leadership Transition and Analyst Outlook
The market is closely watching the upcoming leadership transition. CEO Emma Walmsley is scheduled to step down on December 31, 2025, after transforming GSK into a pure-play biopharma company through the Haleon spin-off. She will be succeeded by Luke Miels, the current Chief Commercial Officer, whose appointment has been interpreted by the market as a vote for continuity and a focus on commercial execution. The stock rose 2-3% on the announcement.
Despite the strong rally, Wall Street consensus remains cautious. Most analysts rate the stock a “Hold,” with an average 12-month price target of $44.13, implying slight downside from its current price near $47.9. This suggests a view that the year's positive developments are largely priced in. In late November, Bank of America upgraded the stock from “underperform” to “neutral,” citing a more balanced risk-reward profile following the Q3 earnings beat and revised guidance.
Broader Context: Capital Allocation and Risk Management
GSK's strategy has been clarified through its capital allocation decisions. In February 2025, the company launched a £2 billion share buyback program and raised its long-term sales ambition to over £40 billion by 2031. This was coupled with a significant de-risking of the company’s legal exposure from the Zantac litigation, with settlement agreements reached for approximately 93% of U.S. state-court claims.
However, the incoming CEO, Luke Miels, faces several key challenges. These include navigating high-profile patent expiries, notably for the HIV drug dolutegravir later in the decade, and intense competition in the vaccines market. The company has already factored a new 15% tariff on European pharma exports to the U.S. into its guidance, highlighting persistent policy risks. The investment narrative has shifted from a deep-value turnaround to that of a fully-valued, income-generating growth company with a dividend yield of approximately 3.5%.
'''
Edgen Stock·Dec 02 2025, 09:52